By using a Crohn’s disease murine model based on the administration of trinitrobenzene sulfonic acid (TNBS)-induction, we demonstrated that CRL 581 β-casein hydrolysate, administered for 10 consecutive days, reduced intestinal inflammatory damage by increasing IL-10 and decreasing IFN-γ production in the gut [70]. Here, IFNG is linked to Crohn disease.